DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Akiba Holdings Co Ltd
TSE:6840
|
JP |
|
K
|
Kemira Oyj
XBER:KEM
|
FI |
|
Toast Inc
NYSE:TOST
|
US |
|
Rigaku Holdings Corp
TSE:268A
|
JP |
|
Top KingWin Ltd
NASDAQ:WAI
|
CN |
|
O
|
Osisko Development Corp
NYSE:ODV
|
CA |
|
Ninestar Corp
SZSE:002180
|
CN |
|
S
|
Sunil Industries Ltd
BSE:521232
|
IN |
|
METISA Metalurgica Timboense SA
BOVESPA:MTSA4
|
BR |
|
V
|
Visa Steel Ltd
NSE:VISASTEEL
|
IN |
|
Usha Martin Education And Solutions Ltd
NSE:UMESLTD
|
IN |
|
D
|
Delta Israel Brands Ltd
TASE:DLTI
|
IL |
|
A
|
Agricola Nacional SAC e I
SGO:ANASAC
|
CL |
|
I
|
ICP Israel Citrus Plantations Ltd
TASE:CTPL1
|
IL |
DiaMedica Therapeutics Inc
Total Liabilities & Equity
DiaMedica Therapeutics Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Total Liabilities & Equity
$57m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
76%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$134B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
See Also
What is DiaMedica Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
57m
USD
Based on the financial report for Sep 30, 2025, DiaMedica Therapeutics Inc's Total Liabilities & Equity amounts to 57m USD.
What is DiaMedica Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
76%
Over the last year, the Total Liabilities & Equity growth was 9%. The average annual Total Liabilities & Equity growth rates for DiaMedica Therapeutics Inc have been 15% over the past three years , 13% over the past five years , and 76% over the past ten years .
